US pharma giant Merck to buy Australian biotech company Viralytics for $394m
Merck acquisition of Viralytics : US pharma giant Merck has made an AUD 502 million ($394 million) deal to acquire Viralytics, an Australian biotech company focused on developing oncolytic immunotherapy treatments for various cancers. Merck will acquire the Australian biotech company through one of its subsidiaries as per the latest pharma acquisition news. Through the […]
The post US pharma giant Merck to buy Australian biotech company Viralytics for $394m appeared first on Business News Today.